RT Journal Article
SR Electronic
T1 Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 183
OP 186
DO 10.20892/j.issn.2095-3941.2017.0017
VO 14
IS 2
A1 Wang, Peng
A1 Xiao, Pei
A1 Ye, Yingnan
A1 Liu, Pengpeng
A1 Han, Lei
A1 Dong, Li
A1 She, Chunhua
A1 Yu, Jinpu
YR 2017
UL http://www.cancerbiomed.org/content/14/2/183.abstract
AB Non-small cell lung cancer (NSCLC) ranks as the leading cause of cancer-related death in the world. Brain metastasis (BM) is a common complication of NSCLC, with 25%–40% of patients developing BM during the course of the disease. A significant strategy of local disease control in the central nervous system is radiation therapy. With the development of precision medicine, the concept of treating lung cancer BM has gradually changed. In this case, we performed a surgical procedure to obtain enough tumor tissue for the detection of the target gene and other related experiments after the patient was informed. Finally, we found that the patient had both hepatocyte growth factor receptor (MET) gene amplification and kinesin light chain 1-anaplastic lymphoma kinase fusion (KLC1-ALK) through next-generation sequencing and showed sensitivity to the targeted therapy of crizotinib. The patient exhibited good response. Our case was successful and underwent targeted therapy with the guidance of precise diagnosis.